Background: Adherence to and tolerance of oral adjuvant endocrine therapy (ET) are important to improve survival for hormone receptor (HR)-positive breast cancer patients. To date, there has been limited literature discussing this issue in elderly patients. Herein we have presented a retrospective study to analyze the tolerance to and completion rate of ET in a single medical center in Taiwan. Patients and methods: From 1996 to 2009, a total of 269 female patients over 70 years of age with primary HR-positive operable breast cancer were registered and analyzed for this study. Results: In our study, the completion rate was 49.4% for all 269 patients and was 56.7% for those willing to initiate ET. Of the 72 patients that discontinued ET early but not due to recurrence, 9.7% had welldocumented ET-related adverse events, 33.3% refused to undergo ET but remained in follow-up, 44.4% did not undergo ET because of loss of follow-up before a complete ET period, and 12.5% of the patients discontinued ET arising from other medical conditions. The switch therapy, tamoxifen followed by aromatase inhibitor, showed a greater completion rate, compared with upfront tamoxifen or aromatase inhibitor. Conclusions: The completion rate for patients who underwent oral ET in our study was similar to previous studies. The switch method of adjuvant oral endocrine therapy demonstrated a better tolerance and adherence in elderly breast cancer patients, compared with tamoxifen or aromatase inhibitor alone.
Introduction
Adjuvant oral endocrine therapy (ET) demonstrates significant survival benefits in postmenopausal breast cancer patients with positive hormone receptor (HR).
1e4 However, some of the patients taking either tamoxifen or aromatase inhibitor (AI) experienced ETrelated adverse events. For tamoxifen, common adverse events include hot flash, endometrial thickening, vaginal spotting or thromboembolic events. 4e6 For AI, arthralgia and loss of bone density may occur. 1,2 These adverse events may affect patients' adherence to a daily pill regimen, not to mention further medication intake for the next five years. Elderly patients, especially those in excess of 70 years of age, are often quite fragile 7 ; such fragility may be secondary to aging or comorbidity. In this "susceptible" patient population, the negative influence of ET-adverse events on patient adherence to a medication regimen can be elevated. 8, 9 This may occur because the drug toxicities could more significantly impact elderly patients with a declining quality of life, compared with the general population. Therefore, the tolerance of and adherence to adjuvant oral endocrine therapy has become an important issue as we continue to treat this patient population and hopefully improve survival. However, there has been limited literature discussing this topic. Therefore, we retrospectively analyzed the completion of and tolerance to adjuvant oral endocrine therapy in elderly early breast cancer patients in a single medical center in Taiwan.
Methods and materials
According to the Cancer Registry Databank of Chang Gung Memorial Hospital, Linkuo branch, a total of 444 elderly female patients with primary early breast cancer were treated between 1996 and 2009. These 444 patients were all above 70 years of age and received curative breast surgery at our institute, either modified radical mastectomy or partial mastectomy. Two hundred and sixtynine of these patients were classified as positive HR, defined by positive estrogen receptor (ER) and/or progesterone receptor (PR).
The pathologic diagnosis of HR-positive primary breast cancer was confirmed by pathologists, based on the customary criteria at that time. Axillary lymph node sampling or dissection could be performed depending upon the surgeon's judgment. Additionally, adjuvant chemotherapy would be recommended if a high risk of recurrence was involved. 10 The choice of chemotherapy regimens, such as modified CMF or anthracycline-based regimens, was also dependent on the decision of each physician. Adjuvant radiotherapy would be suggested if certain factors were present including partial mastectomy, >3 positive lymph node involvement, positive surgical margins, tumor size 5 cm or skin involvement. Oral endocrine therapy was given for patients with HR-positive breast tumors, and the choice of tamoxifen or AI again was based on the decision of the physician. Furthermore, administration of adjuvant treatment, including chemotherapy, radiotherapy and ET, would be discussed with the patients and their families.
We obtained the ages of the patients, the year of diagnosis, TNM stage, status of ER, PR and HER2 and histologic grading from primary chart review. The duration of oral endocrine therapy, causes of discontinuation, and the switches of medications were also recorded. Data was summarized as N (%) for categorical variables, and medians with interquartile ranges (IQR; 25e75%) for continuous characteristics. We used the Chi-square test to compare parameters between different subgroups, and Fisher's exact test for comparisons with small event numbers. Statistic assessments were considered as significance when the p value was less than 0.05. SPSS 22.0 software (SPSS Inc., Chicago, USA) was used for statistic analysis.
Results
A total of 269 female elderly patients over the age of 70 were registered and diagnosed with HR-positive operable primary breast cancer, with a median age of 75 (IQR 72e78). The median follow-up period was 76.4 months. Only 88 patients (32.7%) had no known systemic underlying diseases. One hundred and ninety-four patients (72.1%) had both positive ER and PR, and 55 patients (20.4%) had positive ER but negative PR. There were 21 patients (7.8%) who showed positive PR but negative ER. Other patients' baseline characteristics, including the year of diagnosis, TNM stage, HER2 status and histologic grading, were shown in Table 1 .
Adjuvant chemotherapy was completed in 16.7% of the 252 patients with high recurrent risks; thirty-nine (33.3%) patients received adjuvant radiotherapy.
The completion rate and the time of discontinuation of oral endocrine therapy in elderly patients
One hundred and thirty-three patients took a complete course of oral adjuvant ET. The completion rate of adjuvant oral ET was 49.4% in the intention-to-treat patients in our study, which would increase to 56.7% if only patients willing to initiate ET were taken into account. Neither patients with a larger tumor size (T2-T4), positive lymph node involvement, higher histologic grade (grade 2/ 3), positive HER2 status, known systemic disease, of younger age, nor a complete adjuvant chemotherapy showed a significantly higher completion rate (p ¼ 0.08, 0.46, 0.27, 0.12, 0.50, 0.46, and 0.87, respectively, using the Chi-square test). However, patients with a completed adjuvant radiotherapy presented with a significantly higher rate of a complete ET: 58.8% versus 27.4, p ¼ 0.04. Ninety-eight patients (37.4%) had an ET duration of less than 5 years, 64 patients (24.8%) took oral endocrine agents less than two years, and 38 patients (14.1%) never initiated medication at all (Table 2) .
Twenty-six of the 98 patients had an early discontinuation due to recurrence: there were 14 patients with distant metastasis and 12 with local recurrence. Most distant metastatic events (71.4%) occurred within the initial two years. Of the other 72 patients with early discontinuation of ET, only seven patients (9.7%) had welldocumented ET-related adverse events in the medical records, 24 patients (33.3%) refused to take ET but remained in follow-up, 9 patients (12.5%) were attributed to other medical conditions, and 32 patients (44.4%) were lost in follow-up before a complete ET period (Table 3) . Heart disease * includes atrial fibrillation, ischemic heart disease or congestive heart failure.
No known systemic disease ** means no known diabetes mellitus, stroke, hypertension, heart disease, dementia, liver cirrhosis, chronic lung disease (asthma, chronic obstructive lung disease or bronchiectasis).
The tolerance and choices of the initial endocrine agent
Of the 197 patients who initiated ET with tamoxifen, the completion rate was 57.6%. Thirty-five patients (17.3%) switched to AI from six months to three years after tamoxifen initiation. Fifteen (44.1%) of the patients with switch were attributed to tamoxifenrelated thromboembolic events (stroke, angina, or deep vein thrombosis) or endometrial thickening/vaginal spotting. When patients switched to AI, the completion rate was significantly higher, 79.4% vs. 53.3% for patients with upfront tamoxifen treatment (p ¼ 0.005 by the Chi-square test). Among the patients taking aromatase inhibitor as the initial treatment, the completion rate was 57.6% (Table 3 ).
Discussion
The completion rate of adjuvant endocrine therapy in HRpositive breast cancer in our study was 49.4%, which was similar to previous studies. 11, 12 After patients were excluded for refusing to initiate ET, the overall completion rate further increased. We generally have observed that cancer patients with poor prognostic factors might exhibit improved medical compliance because of the awareness of a potentially poor outcome. To our surprise, this perception was not observed in our elderly patients. In fact, some of the elderly patients might be less concerned about a poor cancerrelated outcome due to limited life expectancy; therefore, they were reluctant to adhere to a pill regimen for five years. Further, the completion rate among patients with known systemic disease was not significantly lower than those without such a disease. We can hypothesize that oral ET was tolerable to elderly patients with systemic comorbidities, so comorbidities were not a determinant factor to adherence of oral ET. What's more, the completion of chemotherapy did not correlate to an adherence with oral ET. As we had believed, the toxicity profile of chemotherapy, like fatigue, neutropenia, diarrhea or microsites, was less favored than that of oral ET. We can conclude that those patients that tolerated adjuvant chemotherapy but not oral ET should not be attributed to the adverse events of oral ET but were likely due to a poor insight of its survival benefits. On the contrary, patients who went through a five-week radiotherapy demonstrated a significant higher completion rate of oral ET. We suggested that the patients with a complete radiotherapy had a greater probability of continuing a "long but durable" treatment like oral ET. Therefore, for elderly patients who cannot complete or refuse adjuvant radiotherapy, we 
"A full course" means a five-year treatment for the majority of patients, except 4 patients diagnosed before 1996 with a two-year treatment.
Table 3
The initial oral endocrine agent and it completion rate.
The initial oral endocrine agent should undertake greater efforts to emphasize the importance and benefits of oral ET. In excess of 40% of patients with early discontinuation stopped taking oral ET due to loss of outpatient follow-up. Thus, we cannot identify why they were not willing to continue their breast cancer follow-up. Furthermore, more than 10% of patients did not even attempt ET after surgery. The two primary reasons why patients may have failed to continue ET therapy were that patients were not provided an adequate overview of the benefits of ET, as well as possible concerns about drug-related adverse events. Therefore, we have suggested that physicians could improve patient adherence to adjuvant ET by better educating their patients about both the survival benefits of the five-year treatment, as well as the early detection of drug-related discomforts.
The switch therapy in our study showed a significantly higher completion rate than upfront tamoxifen treatment. In the upfront group, we noted that some patients could undertake ET, even if ETrelated adverse event occurred, while others could not. This can be explained by the wide variety of frailties and comorbidities among elderly patients. However, in the complete treatment group with switch therapy, the identified tamoxifen-related adverse events exceeded the upfront ones. Therefore, were elderly patients in the switch group healthier than their counterparts in the upfront tamoxifen group? Although we did not show such a similarity by way of the Charlson comorbidity index and performance status in this study, the higher completion rate could be explained by a kind of "mental comfort" with the switch therapy. Once tamoxifenrelated adverse events occurred, they could recur again if patients continued taking the same drug. However, patients were willing to go on ET with another agent, like AI in this study, believing they would not encounter another tamoxifen-related adverse events yet still retain the survival benefits. This could explain why the completion rate was higher in the switch therapy than in the tamoxifen upfront group. According to the BIG 1e98 study, 13 switch therapy presented similar survival benefits with letrozole upfront therapy, regardless of the nodal status. We can concluded that, since the switch therapy in our study showed a higher completion rate, elderly people would derive more survival benefits from switch therapy than upfront therapy. Our study had several limitations. First, it was a retrospective study and data was derived from primary chart review. Accordingly, much of the patient clinical information was unavailable, and the medical staff did not always provide the detailed records that we needed such as the reason for early withdrawal and patient performance status. In fact, many withdrawal events were found without a well-documented reason shown on medical records. Second, the underestimation of ET-related adverse events in this study is significant. Nearly one-third of patients discontinued endocrine therapy directly by failing to later visit our outpatient services department. Consequently, we cannot precisely evaluate the causes of discontinuation in these patients.
Based on the results of this retrospective study, we concluded that the completion rate of oral endocrine therapy in our study was similar to the completion rate in previous studies. Additionally, the switch method of adjuvant oral endocrine therapy demonstrated a better tolerance of and adherence by elderly breast cancer patients, compared with tamoxifen or aromatase inhibitor alone.
